Report Library
View More
Non-Alcoholic Steatohepatitis (NASH...
August 2, 2024
Non-Alcoholic Steatohepatitis (NASH...
August 2, 2024
Non-Alcoholic Steatohepatitis (NASH...
July 19, 2024
Non-Alcoholic Steatohepatitis (NASH...
July 18, 2024
Respiratory Syncytial Virus (RSV) K...
July 17, 2024
Non-Small Cell Lung Cancer (NSCLC) ...
June 28, 2024
NHL: Diffuse Large B-Cell Lymphoma ...
June 27, 2024
NHL: Diffuse Large B-Cell Lymphoma ...
June 26, 2024
Ovarian Cancer KOL Interview - Fran...
June 24, 2024
Ovarian Cancer KOL Interview - US, ...
June 24, 2024
Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 7/29/24 | AstraZeneca (AZN) | Calquence for Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/29/24 | Ventyx Biosciences (VTYX) | VTX-958 for Crohn's Disease | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/29/24 | NewAmsterdam (NAMS) | Obicetrapib for Dyslipidemia / Hypercholesterolemia | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/26/24 | Calliditas Therapeutics (CALT) | Setanaxib for Primary Biliary Cholangitis (PBC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/25/24 | Chemomab Therapeutics (CMMB) | CM-101 for Primary Sclerosing Cholangitis (PSC) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 01/01/25 - 04/30/24 | Subscribers Only | Subscribers Only | Progress Update - Product Launch |
| 01/01/25 - 06/30/24 | Subscribers Only | Subscribers Only | Regulatory - MAA Submission (Europe) |
| 07/31/24 | Subscribers Only | Subscribers Only | Regulatory - Approval Decision (China) |
| 07/31/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
| 07/31/24 | Subscribers Only | Subscribers Only | Regulatory - Meeting with FDA |